Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China

BACKGROUND: Tyrosine kinase inhibitors combined with conventional chemotherapy (CC) in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) has achieved promising efficacy and safety outcomes. The study was conducted to compare the cost-effectiveness between imati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Liu, Lulu, Zhang, Lingli, Lin, Yunzhu, Lu, Xiaoxi, Yang, Hao, Ni, Jiaqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278346/
https://www.ncbi.nlm.nih.gov/pubmed/37331932
http://dx.doi.org/10.1186/s12913-023-09600-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278346/
https://www.ncbi.nlm.nih.gov/pubmed/37331932
http://dx.doi.org/10.1186/s12913-023-09600-7

Ejemplares similares